Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source

G. Hart, Robert; Sharma, Mukul; Mundl, Hardi; E. Kasner, Scott; I. Bangdiwala, Shrikant; D. Berkowitz, Scott; Swaminathan, Balakumar; M. Lavados, Pablo; Wang, Yongjun; Wang, Yilong; Dávalos, Antonio; А. Shamalov, N.; Mikulík, Robert; Cunha, Luís; Lindgren, Arne; Araúz, Antonio; Lang, Wilfried; Członkowska, Anna; Eckstein, Jens; José Gagliardi, Rubens; Amarenco, Pierre; F. Ameriso, Sebastián; Tatlisumak, Turgut; Veltkamp, Roland; J. Hankey, Graeme; Toni, Danilo; Bereczki, Dániel; Uchiyama, Shinichiro; Ntaios, George; Yoon, Byung‐Woo; Brouns, Raf; Endres, Matthias; W. Muir, Keith; M. Bornstein, Natan; Öztürk, Şerefnur; O’Donnell, Martin; M. De Vries Basson, Matthys; Paré, Guillaume; Pater, Calin; Kirsch, Bodo; Sheridan, Patrick; Peters, Gary; I. Weitz, Jeffrey; Frank Peacock, W.; Shoamanesh, Ashkan; Benavente, Oscar; Joyner, Campbell; Themeles, Ellison; J. Connolly, Stuart

doi:10.1056/nejmoa1802686

Public

Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source

Published in New England Journal of Medicine • May 16, 2018

Authors:

Robert G. Hart

Mukul Sharma

Hardi Mundl

Abstract

BACKGROUND: Embolic strokes of undetermined source represent 20% of ischemic strokes and are associated with a high rate of recurrence. Anticoagulant treatment with rivaroxaban, an oral factor Xa inhibitor, may result in a lower risk of recurrent stroke than aspirin. METHODS: We compared the efficac...

Subject

Rivaroxaban

Embolic stroke

Stroke (engine)

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!